Loading…
Reported covered position: Council, Senate HELP and Sen. Chuck Hagel
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: AMERICAN PHARMACIES, INC. · Firm: ROBERTI GLOBAL (F/K/A ROBERTI WHITE, LLC)
Issues related to independent pharmacy, including Medicare and Medicaid reimbursement; H.R. 1, One Big Beautiful Bill Act; H.R. 4317, Pharmacy Benefit Manager (PBM) Reform Act; S. 882, Patients Before Middlemen (PBM) Act; H.R. 5031, Preserving Patient Access to Long-Term Care Pharmacies Act; H.R. 3164/S. 2426, Equitable Community Access to Pharmacist Services (ECAPS) Act; H.R. 2484, Seniors Access to Critical Medications Act; IRA Medicare Drug Price Negotiation program implementation.
Mikaela Naylon Give Kids a Chance Act
Client: BIOTECHNOLOGY INNOVATION ORGANIZATION (BIO) · Firm: ROBERTI GLOBAL (F/K/A ROBERTI WHITE, LLC)
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
NEW AMERICAN INDUSTRIAL ALLIANCE via ROBERTI GLOBAL (F/K/A ROBERTI WHITE, LLC)
2026 · third_quarter · Q3
Permitting reform
Workforce Innovation and Opportunity Act Reauthorization
Workforce Innovation and Opportunity Act Reauthorization
Source: Senate LDA
| AMERISOURCEBERGEN CORPORATION |
| 35 |
| 2014–2022 |
| VALERO ENERGY CORP | 33 | 2019–2026 |
| ORACLE AMERICA, INC. | 30 | 2012–2020 |
| AMGEN | 26 | 2017–2022 |
| SAMSUNG ELECTRONICS AMERICA, INC. | 24 | 2016–2026 |
| ARDELYX INC | 22 | 2020–2026 |
| ASSURED GUARANTY MUNICIPAL CORP. | 20 | 2018–2022 |
| NOVO NORDISK | 20 | 2016–2019 |
| PHOENIX TAILINGS | 20 | 2022–2026 |
| COALITION OPPOSED TO A FEDERAL INSURANCE REGULATOR | 17 | 2011–2014 |
| AMERICAN PHARMACIES, INC. | 16 | 2023–2026 |
| PERFORMANCE BASED BUILDING COALITION | 16 | 2017–2020 |
| COALITION FOR THE ADVANCEMENT OF BRACHYTHERAPY | 15 | 2011–2014 |
| JACKSON NATIONAL LIFE INSURANCE | 15 | 2011–2014 |
| BLUE GENES, LLC | 14 | 2023–2026 |
| CITIGROUP MANAGEMENT CORP | 14 | 2012–2015 |
| MARE FINANCE INVESTMENT HOLDINGS | 14 | 2023–2026 |
| MOTION PICTURE ASSOCIATION OF AMERICA | 14 | 2023–2026 |
| NOVARTIS | 14 | 2011–2014 |
| AARP | 13 | 2012–2014 |
| PALO ALTO NETWORKS, INC. | 12 | 2024–2026 |
| EMD SERONO, INC. | 11 | 2014–2017 |
| AMERICAN COLLEGE OF RADIOLOGY | 8 | 2011–2013 |
| CITIGROUP WASHINGTON, INC. | 6 | 2016 |
| UNITED SAFETY TECHNOLOGY INC | 6 | 2022–2023 |
| CARL ZEISS, INC. | 5 | 2011–2012 |
| INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS | 5 | 2013 |
| INTRAOP MEDICAL CORPORATION | 5 | 2011–2012 |
| PHRMA (PHARMACEUTICAL RESEARCH & MANUFACTURERS OF AMERICA) | 5 | 2021–2022 |
| SERAC HEALTHCARE LTD | 5 | 2022 |
| XOFT INC. | 5 | 2011–2012 |
| GENUS MEDICAL TECHNOLOGIES | 4 | 2022 |
| I AM BOUNDLESS INC | 4 | 2026 |
| PNK DC LLC | 4 | 2026 |
| BORUSAN MANNESMAN PIPE U.S. INC. | 3 | 2014 |
| COUNCIL ON RADIONUCLIDES AND RADIOPHARMACEUTICALS | 3 | 2011 |
| NEW AMERICAN INDUSTRIAL ALLIANCE | 3 | 2026 |
| USA LIVING | 3 | 2014 |
| THE BOEING COMPANY | 2 | 2016–2022 |
| REPUBLIC OF SERBIA | 1 | 2011 |
Issues related to drug pricing, generally; 340B Drug Pricing Program; pharmacy benefit managers; drug patents and patent reporting requirements; H.R. 1262/S. 932, Give Kids a Chance Act.
Mikaela Naylon Give Kids a Chance Act
Client: BIOTECHNOLOGY INNOVATION ORGANIZATION (BIO) · Firm: ROBERTI GLOBAL (F/K/A ROBERTI WHITE, LLC)
Issues related to drug pricing, generally; 340B Drug Pricing Program; pharmacy benefit managers; drug patents and patent reporting requirements; H.R. 1262/S. 932, Give Kids a Chance Act.
DRUG Act
Client: AMERICAN PHARMACIES, INC. · Firm: ROBERTI GLOBAL (F/K/A ROBERTI WHITE, LLC)
Issues related to independent pharmacy, including insurance coverage, network, and reimbursement; S. 526, Pharmacy Benefit Transparency Act; H.R. 2214, Delinking Revenue from Unfair Gouging (DRUG) Act.
Seniors’ Access to Critical Medications Act of 2025
Client: AMERICAN PHARMACIES, INC. · Firm: ROBERTI GLOBAL (F/K/A ROBERTI WHITE, LLC)
Issues related to independent pharmacy, including Medicare and Medicaid reimbursement; H.R. 1, One Big Beautiful Bill Act; H.R. 4317, Pharmacy Benefit Manager (PBM) Reform Act; S. 882, Patients Before Middlemen (PBM) Act; H.R. 5031, Preserving Patient Access to Long-Term Care Pharmacies Act; H.R. 3164/S. 2426, Equitable Community Access to Pharmacist Services (ECAPS) Act; H.R. 2484, Seniors Access to Critical Medications Act; IRA Medicare Drug Price Negotiation program implementation.
Ensuring Community Access to Pharmacist Services Act
Client: AMERICAN PHARMACIES, INC. · Firm: ROBERTI GLOBAL (F/K/A ROBERTI WHITE, LLC)
Issues related to independent pharmacy, including Medicare and Medicaid reimbursement; H.R. 1, One Big Beautiful Bill Act; H.R. 4317, Pharmacy Benefit Manager (PBM) Reform Act; S. 882, Patients Before Middlemen (PBM) Act; H.R. 5031, Preserving Patient Access to Long-Term Care Pharmacies Act; H.R. 3164/S. 2426, Equitable Community Access to Pharmacist Services (ECAPS) Act; H.R. 2484, Seniors Access to Critical Medications Act; IRA Medicare Drug Price Negotiation program implementation.
PBM Reform Act of 2025
Client: AMERICAN PHARMACIES, INC. · Firm: ROBERTI GLOBAL (F/K/A ROBERTI WHITE, LLC)
Issues related to independent pharmacy, including Medicare and Medicaid reimbursement; H.R. 1, One Big Beautiful Bill Act; H.R. 4317, Pharmacy Benefit Manager (PBM) Reform Act; S. 882, Patients Before Middlemen (PBM) Act; H.R. 5031, Preserving Patient Access to Long-Term Care Pharmacies Act; H.R. 3164/S. 2426, Equitable Community Access to Pharmacist Services (ECAPS) Act; H.R. 2484, Seniors Access to Critical Medications Act; IRA Medicare Drug Price Negotiation program implementation.
Preserving Patient Access to Long-Term Care Pharmacies Act
Client: AMERICAN PHARMACIES, INC. · Firm: ROBERTI GLOBAL (F/K/A ROBERTI WHITE, LLC)
Issues related to independent pharmacy, including Medicare and Medicaid reimbursement; H.R. 1, One Big Beautiful Bill Act; H.R. 4317, Pharmacy Benefit Manager (PBM) Reform Act; S. 882, Patients Before Middlemen (PBM) Act; H.R. 5031, Preserving Patient Access to Long-Term Care Pharmacies Act; H.R. 3164/S. 2426, Equitable Community Access to Pharmacist Services (ECAPS) Act; H.R. 2484, Seniors Access to Critical Medications Act; IRA Medicare Drug Price Negotiation program implementation.
Protecting Young Minds Online Act
Client: AT&T SERVICES, INC. · Firm: ROBERTI GLOBAL (F/K/A ROBERTI WHITE, LLC)
FCC Wireless Spectrum Rules Issues related to Handset Exclusivity Issues related to Universal Services Fund Reform Issues related to Text Messaging and Pricing Issues related to Special Access Issues related to Cyber security Issues related+A8:E8 to reimbursement under Medicare Part D// H.R. 5074, the Kidney PATIENT Act Net neutrality rule making Issues concerning broadband connectivity support
Protecting Young Minds Online Act
Client: AT&T SERVICES, INC. · Firm: ROBERTI GLOBAL (F/K/A ROBERTI WHITE, LLC)
FCC Wireless Spectrum Rules Issues related to Handset Exclusivity Issues related to Universal Services Fund Reform Issues related to Text Messaging and Pricing Issues related to Special Access Issues related to Cyber security Issues related+A8:E8 to reimbursement under Medicare Part D// H.R. 5074, the Kidney PATIENT Act Net neutrality rule making Issues concerning broadband connectivity support
Protecting Young Minds Online Act
Client: AT&T SERVICES, INC. · Firm: ROBERTI GLOBAL (F/K/A ROBERTI WHITE, LLC)
FCC Wireless Spectrum Rules Issues related to Handset Exclusivity Issues related to Universal Services Fund Reform Issues related to Text Messaging and Pricing Issues related to Special Access Issues related to Cyber security Issues related+A8:E8 to reimbursement under Medicare Part D// H.R. 5074, the Kidney PATIENT Act Net neutrality rule making Issues concerning broadband connectivity support
National Defense Authorization Act for Fiscal Year 2026
Client: BIOTECHNOLOGY INNOVATION ORGANIZATION (BIO) · Firm: ROBERTI GLOBAL (F/K/A ROBERTI WHITE, LLC)
BIOSECURE Act/S. Amdt. 3236 to S. 2296, the National Defense Authorization Act for FY2026.
National Defense Authorization Act for Fiscal Year 2026
Client: BIOTECHNOLOGY INNOVATION ORGANIZATION (BIO) · Firm: ROBERTI GLOBAL (F/K/A ROBERTI WHITE, LLC)
BIOSECURE Act/S. Amdt. 3236 to S. 2296, the National Defense Authorization Act for FY2026.
Equitable Community Access to Pharmacist Services Act
Client: AMERICAN PHARMACIES, INC. · Firm: ROBERTI GLOBAL (F/K/A ROBERTI WHITE, LLC)
Issues related to independent pharmacy, including Medicare and Medicaid reimbursement; H.R. 1, One Big Beautiful Bill Act; H.R. 4317, Pharmacy Benefit Manager (PBM) Reform Act; S. 882, Patients Before Middlemen (PBM) Act; H.R. 5031, Preserving Patient Access to Long-Term Care Pharmacies Act; H.R. 3164/S. 2426, Equitable Community Access to Pharmacist Services (ECAPS) Act; H.R. 2484, Seniors Access to Critical Medications Act; IRA Medicare Drug Price Negotiation program implementation.
Pharmacy Benefit Manager Transparency Act of 2025
Client: AMERICAN PHARMACIES, INC. · Firm: ROBERTI GLOBAL (F/K/A ROBERTI WHITE, LLC)
Issues related to independent pharmacy, including insurance coverage, network, and reimbursement; S. 526, Pharmacy Benefit Transparency Act; H.R. 2214, Delinking Revenue from Unfair Gouging (DRUG) Act.
Patients Before Middlemen Act
Client: AMERICAN PHARMACIES, INC. · Firm: ROBERTI GLOBAL (F/K/A ROBERTI WHITE, LLC)
Issues related to independent pharmacy, including Medicare and Medicaid reimbursement; H.R. 1, One Big Beautiful Bill Act; H.R. 4317, Pharmacy Benefit Manager (PBM) Reform Act; S. 882, Patients Before Middlemen (PBM) Act; H.R. 5031, Preserving Patient Access to Long-Term Care Pharmacies Act; H.R. 3164/S. 2426, Equitable Community Access to Pharmacist Services (ECAPS) Act; H.R. 2484, Seniors Access to Critical Medications Act; IRA Medicare Drug Price Negotiation program implementation.
Give Kids a Chance Act of 2025
Client: BIOTECHNOLOGY INNOVATION ORGANIZATION (BIO) · Firm: ROBERTI GLOBAL (F/K/A ROBERTI WHITE, LLC)
Issues related to drug pricing, generally; 340B Drug Pricing Program; pharmacy benefit managers; drug patents and patent reporting requirements; H.R. 1262/S. 932, Give Kids a Chance Act.
Give Kids a Chance Act of 2025
Client: BIOTECHNOLOGY INNOVATION ORGANIZATION (BIO) · Firm: ROBERTI GLOBAL (F/K/A ROBERTI WHITE, LLC)
Issues related to drug pricing, generally; 340B Drug Pricing Program; pharmacy benefit managers; drug patents and patent reporting requirements; H.R. 1262/S. 932, Give Kids a Chance Act.
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: AMERICAN PHARMACIES, INC. · Firm: ROBERTI GLOBAL (FKA ROBERTI WHITE, LLC)
Issues related to independent pharmacy, including Medicare and Medicaid reimbursement; H.R. 1, One Big Beautiful Bill Act; H.R. 4317, Pharmacy Benefit Manager (PBM) Reform Act; S. 882, Patients Before Middlemen (PBM) Act; H.R. 5031, Preserving Patient Access to Long-Term Care Pharmacies Act; H.R. 3164/S. 2426, Equitable Community Access to Pharmacist Services (ECAPS) Act; H.R. 2484, Seniors Access to Critical Medications Act; IRA Medicare Drug Price Negotiation program implementation.
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: AMERICAN PHARMACIES, INC. · Firm: ROBERTI GLOBAL (FKA ROBERTI WHITE, LLC)
Issues related to independent pharmacy, including Medicare and Medicaid reimbursement; H.R. 1, One Big Beautiful Bill Act; H.R. 4317, Pharmacy Benefit Manager (PBM) Reform Act; S. 882, Patients Before Middlemen (PBM) Act; H.R. 5031, Preserving Patient Access to Long-Term Care Pharmacies Act; H.R. 3164/S. 2426, Equitable Community Access to Pharmacist Services (ECAPS) Act; H.R. 2484, Seniors Access to Critical Medications Act; IRA Medicare Drug Price Negotiation program implementation.
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: AMERICAN PHARMACIES, INC. · Firm: ROBERTI GLOBAL (FKA ROBERTI WHITE, LLC)
Issues related to independent pharmacy, including Medicare and Medicaid reimbursement; H.R. 1, One Big Beautiful Bill Act
Mikaela Naylon Give Kids a Chance Act
Client: BIOTECHNOLOGY INNOVATION ORGANIZATION (BIO) · Firm: ROBERTI GLOBAL (FKA ROBERTI WHITE, LLC)
Issues related to drug pricing and value, generally Issues related to pharmacy benefit managers and drug rebate reform Issues related to drug patents and patent reporting requirements H.R. 946, the ORPHAN Cures Act H.R. 1262/S. 932, the Give Kids a Chance Act
Mikaela Naylon Give Kids a Chance Act
Client: BIOTECHNOLOGY INNOVATION ORGANIZATION (BIO) · Firm: ROBERTI GLOBAL (FKA ROBERTI WHITE, LLC)
Issues related to drug pricing, generally; 340B Drug Pricing Program; pharmacy benefit managers; drug patents and patent reporting requirements; H.R. 1262/S. 932, Give Kids a Chance Act.
Mikaela Naylon Give Kids a Chance Act
Client: BIOTECHNOLOGY INNOVATION ORGANIZATION (BIO) · Firm: ROBERTI GLOBAL (FKA ROBERTI WHITE, LLC)
Issues related to drug pricing and value, generally Issues related to pharmacy benefit managers and drug rebate reform Issues related to drug patents and patent reporting requirements H.R. 946, the ORPHAN Cures Act H.R. 1262/S. 932, the Give Kids a Chance Act
Mikaela Naylon Give Kids a Chance Act
Client: BIOTECHNOLOGY INNOVATION ORGANIZATION (BIO) · Firm: ROBERTI GLOBAL (FKA ROBERTI WHITE, LLC)
Issues related to drug pricing, generally; 340B Drug Pricing Program; pharmacy benefit managers; drug patents and patent reporting requirements; H.R. 1262/S. 932, Give Kids a Chance Act.
Issues related to independent pharmacy, including insurance coverage, network, and reimbursement; S. 526, Pharmacy Benefit Transparency Act; H.R. 2214, Delinking Revenue from Unfair Gouging (DRUG) Act.
Issues related to independent pharmacy, including insurance coverage, network, and reimbursement; S. 526, Pharmacy Benefit Transparency Act; H.R. 2214, Delinking Revenue from Unfair Gouging (DRUG) Act.
Seniors’ Access to Critical Medications Act of 2025
Client: AMERICAN PHARMACIES, INC. · Firm: ROBERTI GLOBAL (FKA ROBERTI WHITE, LLC)
Issues related to independent pharmacy, including Medicare and Medicaid reimbursement; H.R. 1, One Big Beautiful Bill Act; H.R. 4317, Pharmacy Benefit Manager (PBM) Reform Act; S. 882, Patients Before Middlemen (PBM) Act; H.R. 5031, Preserving Patient Access to Long-Term Care Pharmacies Act; H.R. 3164/S. 2426, Equitable Community Access to Pharmacist Services (ECAPS) Act; H.R. 2484, Seniors Access to Critical Medications Act; IRA Medicare Drug Price Negotiation program implementation.
Seniors’ Access to Critical Medications Act of 2025
Client: AMERICAN PHARMACIES, INC. · Firm: ROBERTI GLOBAL (FKA ROBERTI WHITE, LLC)
Issues related to independent pharmacy, including Medicare and Medicaid reimbursement; H.R. 1, One Big Beautiful Bill Act; H.R. 4317, Pharmacy Benefit Manager (PBM) Reform Act; S. 882, Patients Before Middlemen (PBM) Act; H.R. 5031, Preserving Patient Access to Long-Term Care Pharmacies Act; H.R. 3164/S. 2426, Equitable Community Access to Pharmacist Services (ECAPS) Act; H.R. 2484, Seniors Access to Critical Medications Act; IRA Medicare Drug Price Negotiation program implementation.
Ensuring Community Access to Pharmacist Services Act
Client: AMERICAN PHARMACIES, INC. · Firm: ROBERTI GLOBAL (FKA ROBERTI WHITE, LLC)
Issues related to independent pharmacy, including Medicare and Medicaid reimbursement; H.R. 1, One Big Beautiful Bill Act; H.R. 4317, Pharmacy Benefit Manager (PBM) Reform Act; S. 882, Patients Before Middlemen (PBM) Act; H.R. 5031, Preserving Patient Access to Long-Term Care Pharmacies Act; H.R. 3164/S. 2426, Equitable Community Access to Pharmacist Services (ECAPS) Act; H.R. 2484, Seniors Access to Critical Medications Act; IRA Medicare Drug Price Negotiation program implementation.
Ensuring Community Access to Pharmacist Services Act
Client: AMERICAN PHARMACIES, INC. · Firm: ROBERTI GLOBAL (FKA ROBERTI WHITE, LLC)
Issues related to independent pharmacy, including Medicare and Medicaid reimbursement; H.R. 1, One Big Beautiful Bill Act; H.R. 4317, Pharmacy Benefit Manager (PBM) Reform Act; S. 882, Patients Before Middlemen (PBM) Act; H.R. 5031, Preserving Patient Access to Long-Term Care Pharmacies Act; H.R. 3164/S. 2426, Equitable Community Access to Pharmacist Services (ECAPS) Act; H.R. 2484, Seniors Access to Critical Medications Act; IRA Medicare Drug Price Negotiation program implementation.
PBM Reform Act of 2025
Client: AMERICAN PHARMACIES, INC. · Firm: ROBERTI GLOBAL (FKA ROBERTI WHITE, LLC)
Issues related to independent pharmacy, including Medicare and Medicaid reimbursement; H.R. 1, One Big Beautiful Bill Act; H.R. 4317, Pharmacy Benefit Manager (PBM) Reform Act; S. 882, Patients Before Middlemen (PBM) Act; H.R. 5031, Preserving Patient Access to Long-Term Care Pharmacies Act; H.R. 3164/S. 2426, Equitable Community Access to Pharmacist Services (ECAPS) Act; H.R. 2484, Seniors Access to Critical Medications Act; IRA Medicare Drug Price Negotiation program implementation.
PBM Reform Act of 2025
Client: AMERICAN PHARMACIES, INC. · Firm: ROBERTI GLOBAL (FKA ROBERTI WHITE, LLC)
Issues related to independent pharmacy, including Medicare and Medicaid reimbursement; H.R. 1, One Big Beautiful Bill Act; H.R. 4317, Pharmacy Benefit Manager (PBM) Reform Act; S. 882, Patients Before Middlemen (PBM) Act; H.R. 5031, Preserving Patient Access to Long-Term Care Pharmacies Act; H.R. 3164/S. 2426, Equitable Community Access to Pharmacist Services (ECAPS) Act; H.R. 2484, Seniors Access to Critical Medications Act; IRA Medicare Drug Price Negotiation program implementation.
Preserving Patient Access to Long-Term Care Pharmacies Act
Client: AMERICAN PHARMACIES, INC. · Firm: ROBERTI GLOBAL (FKA ROBERTI WHITE, LLC)
Issues related to independent pharmacy, including Medicare and Medicaid reimbursement; H.R. 1, One Big Beautiful Bill Act; H.R. 4317, Pharmacy Benefit Manager (PBM) Reform Act; S. 882, Patients Before Middlemen (PBM) Act; H.R. 5031, Preserving Patient Access to Long-Term Care Pharmacies Act; H.R. 3164/S. 2426, Equitable Community Access to Pharmacist Services (ECAPS) Act; H.R. 2484, Seniors Access to Critical Medications Act; IRA Medicare Drug Price Negotiation program implementation.
Preserving Patient Access to Long-Term Care Pharmacies Act
Client: AMERICAN PHARMACIES, INC. · Firm: ROBERTI GLOBAL (FKA ROBERTI WHITE, LLC)
Issues related to independent pharmacy, including Medicare and Medicaid reimbursement; H.R. 1, One Big Beautiful Bill Act; H.R. 4317, Pharmacy Benefit Manager (PBM) Reform Act; S. 882, Patients Before Middlemen (PBM) Act; H.R. 5031, Preserving Patient Access to Long-Term Care Pharmacies Act; H.R. 3164/S. 2426, Equitable Community Access to Pharmacist Services (ECAPS) Act; H.R. 2484, Seniors Access to Critical Medications Act; IRA Medicare Drug Price Negotiation program implementation.
Protecting Young Minds Online Act
Client: AT&T SERVICES, INC. · Firm: ROBERTI GLOBAL (FKA ROBERTI WHITE, LLC)
FCC Wireless Spectrum Rules Issues related to Handset Exclusivity Issues related to Universal Services Fund Reform Issues related to Text Messaging and Pricing Issues related to Special Access Issues related to Cyber security Issues related+A8:E8 to reimbursement under Medicare Part D// H.R. 5074, the Kidney PATIENT Act Net neutrality rule making Issues concerning broadband connectivity support
Protecting Young Minds Online Act
Client: ARDELYX, INC. · Firm: ROBERTI GLOBAL (FKA ROBERTI WHITE, LLC)
Issues related to reimbursement under Medicare Part D; H.R. 5074/S.4510, the Kidney PATIENT Act
Protecting Young Minds Online Act
Client: AT&T SERVICES, INC. · Firm: ROBERTI GLOBAL (FKA ROBERTI WHITE, LLC)
FCC Wireless Spectrum Rules Issues related to Handset Exclusivity Issues related to Universal Services Fund Reform Issues related to Text Messaging and Pricing Issues related to Special Access Issues related to Cyber security Issues related+A8:E8 to reimbursement under Medicare Part D// H.R. 5074, the Kidney PATIENT Act Net neutrality rule making Issues concerning broadband connectivity support
Protecting Young Minds Online Act
Client: AT&T SERVICES, INC. · Firm: ROBERTI GLOBAL (FKA ROBERTI WHITE, LLC)
FCC Wireless Spectrum Rules Issues related to Handset Exclusivity Issues related to Universal Services Fund Reform Issues related to Text Messaging and Pricing Issues related to Special Access Issues related to Cyber security Issues related+A8:E8 to reimbursement under Medicare Part D// H.R. 5074, the Kidney PATIENT Act Net neutrality rule making Issues concerning broadband connectivity support
Protecting Young Minds Online Act
Client: AT&T SERVICES, INC. · Firm: ROBERTI GLOBAL (FKA ROBERTI WHITE, LLC)
FCC Wireless Spectrum Rules Issues related to Handset Exclusivity Issues related to Universal Services Fund Reform Issues related to Text Messaging and Pricing Issues related to Special Access Issues related to Cyber security Issues related+A8:E8 to reimbursement under Medicare Part D// H.R. 5074, the Kidney PATIENT Act Net neutrality rule making Issues concerning broadband connectivity support
ORPHAN Cures Act
Client: BIOTECHNOLOGY INNOVATION ORGANIZATION (BIO) · Firm: ROBERTI GLOBAL (FKA ROBERTI WHITE, LLC)
Issues related to drug pricing and value, generally Issues related to pharmacy benefit managers and drug rebate reform Issues related to drug patents and patent reporting requirements H.R. 946, the ORPHAN Cures Act H.R. 1262/S. 932, the Give Kids a Chance Act
ORPHAN Cures Act
Client: BIOTECHNOLOGY INNOVATION ORGANIZATION (BIO) · Firm: ROBERTI GLOBAL (FKA ROBERTI WHITE, LLC)
Issues related to drug pricing and value, generally Issues related to pharmacy benefit managers and drug rebate reform Issues related to drug patents and patent reporting requirements H.R. 946, the ORPHAN Cures Act H.R. 1262/S. 932, the Give Kids a Chance Act
National Defense Authorization Act for Fiscal Year 2026
Client: BIOTECHNOLOGY INNOVATION ORGANIZATION (BIO) · Firm: ROBERTI GLOBAL (FKA ROBERTI WHITE, LLC)
BIOSECURE Act/S. Amdt. 3236 to S. 2296, the National Defense Authorization Act for FY2026.
National Defense Authorization Act for Fiscal Year 2026
Client: BIOTECHNOLOGY INNOVATION ORGANIZATION (BIO) · Firm: ROBERTI GLOBAL (FKA ROBERTI WHITE, LLC)
BIOSECURE Act/S. Amdt. 3236 to S. 2296, the National Defense Authorization Act for FY2026.
Equitable Community Access to Pharmacist Services Act
Client: AMERICAN PHARMACIES, INC. · Firm: ROBERTI GLOBAL (FKA ROBERTI WHITE, LLC)
Issues related to independent pharmacy, including Medicare and Medicaid reimbursement; H.R. 1, One Big Beautiful Bill Act; H.R. 4317, Pharmacy Benefit Manager (PBM) Reform Act; S. 882, Patients Before Middlemen (PBM) Act; H.R. 5031, Preserving Patient Access to Long-Term Care Pharmacies Act; H.R. 3164/S. 2426, Equitable Community Access to Pharmacist Services (ECAPS) Act; H.R. 2484, Seniors Access to Critical Medications Act; IRA Medicare Drug Price Negotiation program implementation.
Equitable Community Access to Pharmacist Services Act
Client: AMERICAN PHARMACIES, INC. · Firm: ROBERTI GLOBAL (FKA ROBERTI WHITE, LLC)
Issues related to independent pharmacy, including Medicare and Medicaid reimbursement; H.R. 1, One Big Beautiful Bill Act; H.R. 4317, Pharmacy Benefit Manager (PBM) Reform Act; S. 882, Patients Before Middlemen (PBM) Act; H.R. 5031, Preserving Patient Access to Long-Term Care Pharmacies Act; H.R. 3164/S. 2426, Equitable Community Access to Pharmacist Services (ECAPS) Act; H.R. 2484, Seniors Access to Critical Medications Act; IRA Medicare Drug Price Negotiation program implementation.
Relief for Families of the Fallen Act
Client: ARDELYX, INC. · Firm: ROBERTI GLOBAL (FKA ROBERTI WHITE, LLC)
Issues related to reimbursement under Medicare Part D; H.R. 5074/S.4510, the Kidney PATIENT Act
Pharmacy Benefit Manager Transparency Act of 2025
Client: AMERICAN PHARMACIES, INC. · Firm: ROBERTI GLOBAL (FKA ROBERTI WHITE, LLC)
Issues related to independent pharmacy, including insurance coverage, network, and reimbursement; S. 526, Pharmacy Benefit Transparency Act; H.R. 2214, Delinking Revenue from Unfair Gouging (DRUG) Act.
Pharmacy Benefit Manager Transparency Act of 2025
Client: AMERICAN PHARMACIES, INC. · Firm: ROBERTI GLOBAL (FKA ROBERTI WHITE, LLC)
Issues related to independent pharmacy, including insurance coverage, network, and reimbursement; S. 526, Pharmacy Benefit Transparency Act; H.R. 2214, Delinking Revenue from Unfair Gouging (DRUG) Act.
Patients Before Middlemen Act
Client: AMERICAN PHARMACIES, INC. · Firm: ROBERTI GLOBAL (FKA ROBERTI WHITE, LLC)
Issues related to independent pharmacy, including Medicare and Medicaid reimbursement; H.R. 1, One Big Beautiful Bill Act; H.R. 4317, Pharmacy Benefit Manager (PBM) Reform Act; S. 882, Patients Before Middlemen (PBM) Act; H.R. 5031, Preserving Patient Access to Long-Term Care Pharmacies Act; H.R. 3164/S. 2426, Equitable Community Access to Pharmacist Services (ECAPS) Act; H.R. 2484, Seniors Access to Critical Medications Act; IRA Medicare Drug Price Negotiation program implementation.
Patients Before Middlemen Act
Client: AMERICAN PHARMACIES, INC. · Firm: ROBERTI GLOBAL (FKA ROBERTI WHITE, LLC)
Issues related to independent pharmacy, including Medicare and Medicaid reimbursement; H.R. 1, One Big Beautiful Bill Act; H.R. 4317, Pharmacy Benefit Manager (PBM) Reform Act; S. 882, Patients Before Middlemen (PBM) Act; H.R. 5031, Preserving Patient Access to Long-Term Care Pharmacies Act; H.R. 3164/S. 2426, Equitable Community Access to Pharmacist Services (ECAPS) Act; H.R. 2484, Seniors Access to Critical Medications Act; IRA Medicare Drug Price Negotiation program implementation.
Give Kids a Chance Act of 2025
Client: BIOTECHNOLOGY INNOVATION ORGANIZATION (BIO) · Firm: ROBERTI GLOBAL (FKA ROBERTI WHITE, LLC)
Issues related to drug pricing, generally; 340B Drug Pricing Program; pharmacy benefit managers; drug patents and patent reporting requirements; H.R. 1262/S. 932, Give Kids a Chance Act.
Give Kids a Chance Act of 2025
Client: BIOTECHNOLOGY INNOVATION ORGANIZATION (BIO) · Firm: ROBERTI GLOBAL (FKA ROBERTI WHITE, LLC)
Issues related to drug pricing and value, generally Issues related to pharmacy benefit managers and drug rebate reform Issues related to drug patents and patent reporting requirements H.R. 946, the ORPHAN Cures Act H.R. 1262/S. 932, the Give Kids a Chance Act
Give Kids a Chance Act of 2025
Client: BIOTECHNOLOGY INNOVATION ORGANIZATION (BIO) · Firm: ROBERTI GLOBAL (FKA ROBERTI WHITE, LLC)
Issues related to drug pricing, generally; 340B Drug Pricing Program; pharmacy benefit managers; drug patents and patent reporting requirements; H.R. 1262/S. 932, Give Kids a Chance Act.
Give Kids a Chance Act of 2025
Client: BIOTECHNOLOGY INNOVATION ORGANIZATION (BIO) · Firm: ROBERTI GLOBAL (FKA ROBERTI WHITE, LLC)
Issues related to drug pricing and value, generally Issues related to pharmacy benefit managers and drug rebate reform Issues related to drug patents and patent reporting requirements H.R. 946, the ORPHAN Cures Act H.R. 1262/S. 932, the Give Kids a Chance Act
Kidney PATIENT Act of 2023
Client: ARDELYX, INC. · Firm: ROBERTI GLOBAL (F/K/A ROBERTI WHITE, LLC)
Issues related to reimbursement under Medicare Part D H.R. 5074, the Kidney PATIENT Act
Kidney PATIENT Act of 2023
Client: ARDELYX, INC. · Firm: ROBERTI GLOBAL (F/K/A ROBERTI WHITE, LLC)
Issues related to reimbursement under Medicare Part D H.R. 5074, the Kidney PATIENT Act
Kidney PATIENT Act of 2023
Client: ARDELYX, INC. · Firm: ROBERTI GLOBAL (F/K/A ROBERTI WHITE, LLC)
Issues related to reimbursement under Medicare Part D H.R. 5074, the Kidney PATIENT Act
Kidney PATIENT Act of 2023
Client: ARDELYX, INC. · Firm: ROBERTI GLOBAL (F/K/A ROBERTI WHITE, LLC)
Issues related to reimbursement under Medicare Part D; H.R. 5074/S.4510, the Kidney PATIENT Act
Lower Costs, More Transparency Act
Client: AMERICAN PHARMACIES, INC. · Firm: ROBERTI GLOBAL (F/K/A ROBERTI WHITE, LLC)
Issues related to independent pharmacy, including Medicare and Medicaid reimbursement; H.R. 5378, the Lower Costs, More Transparency Act; S. 1339, the PBM Reform Act; S. 3430, the Better Mental Health Care, Lower-Cost Drugs & Extenders Act; S. 2973, the Modernizing & Ensuring PBM Accountability Act
Lower Costs, More Transparency Act
Client: AMERICAN PHARMACIES, INC. · Firm: ROBERTI GLOBAL (F/K/A ROBERTI WHITE, LLC)
Issues related to independent pharmacy, including Medicare and Medicaid reimbursement; H.R. 5378, the Lower Costs, More Transparency Act; S. 1339, the PBM Reform Act; S. 3430, the Better Mental Health Care, Lower-Cost Drugs & Extenders Act; S. 2973, the Modernizing & Ensuring PBM Accountability Act
Lower Costs, More Transparency Act
Client: AMERICAN PHARMACIES, INC. · Firm: ROBERTI GLOBAL (F/K/A ROBERTI WHITE, LLC)
Issues related to independent pharmacy, including Medicare and Medicaid reimbursement; H.R. 5378, the Lower Costs, More Transparency Act; S. 1339, the PBM Reform Act; S. 3430, the Better Mental Health Care, Lower-Cost Drugs & Extenders Act; S. 2973, the Modernizing & Ensuring PBM Accountability Act
Lower Costs, More Transparency Act
Client: AMERICAN PHARMACIES, INC. · Firm: ROBERTI GLOBAL (F/K/A ROBERTI WHITE, LLC)
Issues related to independent pharmacy, including Medicare and Medicaid reimbursement; H.R. 5378, the Lower Costs, More Transparency Act; S. 1339, the PBM Reform Act; S. 3430, the Better Mental Health Care, Lower-Cost Drugs & Extenders Act; S. 2973, the Modernizing & Ensuring PBM Accountability Act
WARM Act of 2023
Client: ASTELLAS PHARMA US, INC. · Firm: ROBERTI GLOBAL (F/K/A ROBERTI WHITE, LLC)
Issues related to march-in rights under the Bayh-Dole Act (Pub. L. 96-517) Women's health issues; WARM Act (H.R. 6743)
Creating Hope Reauthorization Act of 2024
Client: BIOTECHNOLOGY INNOVATION ORGANIZATION (BIO) · Firm: ROBERTI GLOBAL (F/K/A ROBERTI WHITE, LLC)
Issues related to drug pricing and value, generally Issues related to pharmacy benefit managers and drug rebate reform Issues related to drug patents and patent reporting requirements Issues related to march-in rights under the Bayh-Dole Act (Pub. L. 96-517) Creating Hope Reauthorization Act (H.R. 7384/S. 4583) Promising Pathway Act 2.0 (S.4426)
Creating Hope Reauthorization Act of 2024
Client: BIOTECHNOLOGY INNOVATION ORGANIZATION (BIO) · Firm: ROBERTI GLOBAL (F/K/A ROBERTI WHITE, LLC)
Issues related to drug pricing and value, generally Issues related to pharmacy benefit managers and drug rebate reform Issues related to drug patents and patent reporting requirements Issues related to march-in rights under the Bayh-Dole Act (Pub. L. 96-517) Creating Hope Reauthorization Act (H.R. 7384/S. 4583) Promising Pathway Act 2.0 (S.4426)
Pharmacy Benefit Manager Reform Act
Client: AMERICAN PHARMACIES, INC. · Firm: ROBERTI GLOBAL (F/K/A ROBERTI WHITE, LLC)
Issues related to independent pharmacy, including Medicare and Medicaid reimbursement; H.R. 5378, the Lower Costs, More Transparency Act; S. 1339, the PBM Reform Act; S. 3430, the Better Mental Health Care, Lower-Cost Drugs & Extenders Act; S. 2973, the Modernizing & Ensuring PBM Accountability Act
Pharmacy Benefit Manager Reform Act
Client: AMERICAN PHARMACIES, INC. · Firm: ROBERTI GLOBAL (F/K/A ROBERTI WHITE, LLC)
Issues related to independent pharmacy, including Medicare and Medicaid reimbursement; H.R. 5378, the Lower Costs, More Transparency Act; S. 1339, the PBM Reform Act; S. 3430, the Better Mental Health Care, Lower-Cost Drugs & Extenders Act; S. 2973, the Modernizing & Ensuring PBM Accountability Act
Pharmacy Benefit Manager Reform Act
Client: AMERICAN PHARMACIES, INC. · Firm: ROBERTI GLOBAL (F/K/A ROBERTI WHITE, LLC)
Issues related to independent pharmacy, including Medicare and Medicaid reimbursement; H.R. 5378, the Lower Costs, More Transparency Act; S. 1339, the PBM Reform Act; S. 3430, the Better Mental Health Care, Lower-Cost Drugs & Extenders Act; S. 2973, the Modernizing & Ensuring PBM Accountability Act
Pharmacy Benefit Manager Reform Act
Client: AMERICAN PHARMACIES, INC. · Firm: ROBERTI GLOBAL (F/K/A ROBERTI WHITE, LLC)
Issues related to independent pharmacy, including Medicare and Medicaid reimbursement; H.R. 5378, the Lower Costs, More Transparency Act; S. 1339, the PBM Reform Act; S. 3430, the Better Mental Health Care, Lower-Cost Drugs & Extenders Act; S. 2973, the Modernizing & Ensuring PBM Accountability Act
Modernizing and Ensuring PBM Accountability Act
Client: AMERICAN PHARMACIES, INC. · Firm: ROBERTI GLOBAL (F/K/A ROBERTI WHITE, LLC)
Issues related to independent pharmacy, including Medicare and Medicaid reimbursement; H.R. 5378, the Lower Costs, More Transparency Act; S. 1339, the PBM Reform Act; S. 3430, the Better Mental Health Care, Lower-Cost Drugs & Extenders Act; S. 2973, the Modernizing & Ensuring PBM Accountability Act
Modernizing and Ensuring PBM Accountability Act
Client: AMERICAN PHARMACIES, INC. · Firm: ROBERTI GLOBAL (F/K/A ROBERTI WHITE, LLC)
Issues related to independent pharmacy, including Medicare and Medicaid reimbursement; H.R. 5378, the Lower Costs, More Transparency Act; S. 1339, the PBM Reform Act; S. 3430, the Better Mental Health Care, Lower-Cost Drugs & Extenders Act; S. 2973, the Modernizing & Ensuring PBM Accountability Act
Modernizing and Ensuring PBM Accountability Act
Client: AMERICAN PHARMACIES, INC. · Firm: ROBERTI GLOBAL (F/K/A ROBERTI WHITE, LLC)
Issues related to independent pharmacy, including Medicare and Medicaid reimbursement; H.R. 5378, the Lower Costs, More Transparency Act; S. 1339, the PBM Reform Act; S. 3430, the Better Mental Health Care, Lower-Cost Drugs & Extenders Act; S. 2973, the Modernizing & Ensuring PBM Accountability Act
Modernizing and Ensuring PBM Accountability Act
Client: AMERICAN PHARMACIES, INC. · Firm: ROBERTI GLOBAL (F/K/A ROBERTI WHITE, LLC)
Issues related to independent pharmacy, including Medicare and Medicaid reimbursement; H.R. 5378, the Lower Costs, More Transparency Act; S. 1339, the PBM Reform Act; S. 3430, the Better Mental Health Care, Lower-Cost Drugs & Extenders Act; S. 2973, the Modernizing & Ensuring PBM Accountability Act
Better Mental Health Care, Lower-Cost Drugs, and Extenders Act of 2023
Client: AMERICAN PHARMACIES, INC. · Firm: ROBERTI GLOBAL (F/K/A ROBERTI WHITE, LLC)
Issues related to independent pharmacy, including Medicare and Medicaid reimbursement; H.R. 5378, the Lower Costs, More Transparency Act; S. 1339, the PBM Reform Act; S. 3430, the Better Mental Health Care, Lower-Cost Drugs & Extenders Act; S. 2973, the Modernizing & Ensuring PBM Accountability Act
Better Mental Health Care, Lower-Cost Drugs, and Extenders Act of 2023
Client: AMERICAN PHARMACIES, INC. · Firm: ROBERTI GLOBAL (F/K/A ROBERTI WHITE, LLC)
Issues related to independent pharmacy, including Medicare and Medicaid reimbursement; H.R. 5378, the Lower Costs, More Transparency Act; S. 1339, the PBM Reform Act; S. 3430, the Better Mental Health Care, Lower-Cost Drugs & Extenders Act; S. 2973, the Modernizing & Ensuring PBM Accountability Act
Better Mental Health Care, Lower-Cost Drugs, and Extenders Act of 2023
Client: AMERICAN PHARMACIES, INC. · Firm: ROBERTI GLOBAL (F/K/A ROBERTI WHITE, LLC)
Issues related to independent pharmacy, including Medicare and Medicaid reimbursement; H.R. 5378, the Lower Costs, More Transparency Act; S. 1339, the PBM Reform Act; S. 3430, the Better Mental Health Care, Lower-Cost Drugs & Extenders Act; S. 2973, the Modernizing & Ensuring PBM Accountability Act
Better Mental Health Care, Lower-Cost Drugs, and Extenders Act of 2023
Client: AMERICAN PHARMACIES, INC. · Firm: ROBERTI GLOBAL (F/K/A ROBERTI WHITE, LLC)
Issues related to independent pharmacy, including Medicare and Medicaid reimbursement; H.R. 5378, the Lower Costs, More Transparency Act; S. 1339, the PBM Reform Act; S. 3430, the Better Mental Health Care, Lower-Cost Drugs & Extenders Act; S. 2973, the Modernizing & Ensuring PBM Accountability Act
Promising Pathway Act 2.0
Client: BIOTECHNOLOGY INNOVATION ORGANIZATION (BIO) · Firm: ROBERTI GLOBAL (F/K/A ROBERTI WHITE, LLC)
Issues related to drug pricing and value, generally Issues related to pharmacy benefit managers and drug rebate reform Issues related to drug patents and patent reporting requirements Issues related to march-in rights under the Bayh-Dole Act (Pub. L. 96-517) Creating Hope Reauthorization Act (H.R. 7384/S. 4583) Promising Pathway Act 2.0 (S.4426)
Promising Pathway Act 2.0
Client: BIOTECHNOLOGY INNOVATION ORGANIZATION (BIO) · Firm: ROBERTI GLOBAL (F/K/A ROBERTI WHITE, LLC)
Issues related to drug pricing and value, generally Issues related to pharmacy benefit managers and drug rebate reform Issues related to drug patents and patent reporting requirements Issues related to march-in rights under the Bayh-Dole Act (Pub. L. 96-517) Creating Hope Reauthorization Act (H.R. 7384/S. 4583) Promising Pathway Act 2.0 (S.4426)
Kidney PATIENT Act of 2024
Client: ARDELYX, INC. · Firm: ROBERTI GLOBAL (F/K/A ROBERTI WHITE, LLC)
Issues related to reimbursement under Medicare Part D; H.R. 5074/S.4510, the Kidney PATIENT Act
Creating Hope Reauthorization Act of 2024
Client: BIOTECHNOLOGY INNOVATION ORGANIZATION (BIO) · Firm: ROBERTI GLOBAL (F/K/A ROBERTI WHITE, LLC)
Issues related to drug pricing and value, generally Issues related to pharmacy benefit managers and drug rebate reform Issues related to drug patents and patent reporting requirements Issues related to march-in rights under the Bayh-Dole Act (Pub. L. 96-517) Creating Hope Reauthorization Act (H.R. 7384/S. 4583) Promising Pathway Act 2.0 (S.4426)
Creating Hope Reauthorization Act of 2024
Client: BIOTECHNOLOGY INNOVATION ORGANIZATION (BIO) · Firm: ROBERTI GLOBAL (F/K/A ROBERTI WHITE, LLC)
Issues related to drug pricing and value, generally Issues related to pharmacy benefit managers and drug rebate reform Issues related to drug patents and patent reporting requirements Issues related to march-in rights under the Bayh-Dole Act (Pub. L. 96-517) Creating Hope Reauthorization Act (H.R. 7384/S. 4583) Promising Pathway Act 2.0 (S.4426)
Drug Price Transparency in Medicaid Act of 2023
Client: AMERICAN PHARMACIES, INC. · Firm: ROBERTI GLOBAL (F/K/A ROBERTI WHITE, LLC)
legislative and regulatory issues related to independent pharmacy and pharmacy benefit managers (PBMs). H.R. 1613/S. 1038, Drug Price Transparency in Medicaid Act H.R. 2816, PBM Sunshine and Accountability Act H.R. 2880, Protecting Patients from PBM Abuses Act H.R. 3285, Fairness for Patient Medications Act H.R. 3561, Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act H.R. 5378, Lower Costs, More Transparency Act S. 1339, PBM Reform Act S. 1542, DRUG Act S. 2973, Modernizing and Ensuring PBM Accountability (MEPA) Act S. 3430, Better Mental Health Care, Lower-Cost Drugs & Extenders Act
Drug Price Transparency in Medicaid Act of 2023
Client: AMERICAN PHARMACIES, INC. · Firm: ROBERTI GLOBAL (F/K/A ROBERTI WHITE, LLC)
Legislative and regulatory issues related to independent pharmacies. H.R. 1613/S. 1038, Drug Price Transparency in Medicaid Act
Pharmacy Benefit Manager Sunshine and Accountability Act
Client: AMERICAN PHARMACIES, INC. · Firm: ROBERTI GLOBAL (F/K/A ROBERTI WHITE, LLC)
legislative and regulatory issues related to independent pharmacy and pharmacy benefit managers (PBMs). H.R. 1613/S. 1038, Drug Price Transparency in Medicaid Act H.R. 2816, PBM Sunshine and Accountability Act H.R. 2880, Protecting Patients from PBM Abuses Act H.R. 3285, Fairness for Patient Medications Act H.R. 3561, Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act H.R. 5378, Lower Costs, More Transparency Act S. 1339, PBM Reform Act S. 1542, DRUG Act S. 2973, Modernizing and Ensuring PBM Accountability (MEPA) Act S. 3430, Better Mental Health Care, Lower-Cost Drugs & Extenders Act
Protecting Patients Against PBM Abuses Act
Client: AMERICAN PHARMACIES, INC. · Firm: ROBERTI GLOBAL (F/K/A ROBERTI WHITE, LLC)
legislative and regulatory issues related to independent pharmacy and pharmacy benefit managers (PBMs). H.R. 1613/S. 1038, Drug Price Transparency in Medicaid Act H.R. 2816, PBM Sunshine and Accountability Act H.R. 2880, Protecting Patients from PBM Abuses Act H.R. 3285, Fairness for Patient Medications Act H.R. 3561, Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act H.R. 5378, Lower Costs, More Transparency Act S. 1339, PBM Reform Act S. 1542, DRUG Act S. 2973, Modernizing and Ensuring PBM Accountability (MEPA) Act S. 3430, Better Mental Health Care, Lower-Cost Drugs & Extenders Act
Fairness for Patient Medications Act
Client: AMERICAN PHARMACIES, INC. · Firm: ROBERTI GLOBAL (F/K/A ROBERTI WHITE, LLC)
legislative and regulatory issues related to independent pharmacy and pharmacy benefit managers (PBMs). H.R. 1613/S. 1038, Drug Price Transparency in Medicaid Act H.R. 2816, PBM Sunshine and Accountability Act H.R. 2880, Protecting Patients from PBM Abuses Act H.R. 3285, Fairness for Patient Medications Act H.R. 3561, Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act H.R. 5378, Lower Costs, More Transparency Act S. 1339, PBM Reform Act S. 1542, DRUG Act S. 2973, Modernizing and Ensuring PBM Accountability (MEPA) Act S. 3430, Better Mental Health Care, Lower-Cost Drugs & Extenders Act
PATIENT Act of 2023
Client: AMERICAN PHARMACIES, INC. · Firm: ROBERTI GLOBAL (F/K/A ROBERTI WHITE, LLC)
legislative and regulatory issues related to independent pharmacy and pharmacy benefit managers (PBMs). H.R. 1613/S. 1038, Drug Price Transparency in Medicaid Act H.R. 2816, PBM Sunshine and Accountability Act H.R. 2880, Protecting Patients from PBM Abuses Act H.R. 3285, Fairness for Patient Medications Act H.R. 3561, Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act H.R. 5378, Lower Costs, More Transparency Act S. 1339, PBM Reform Act S. 1542, DRUG Act S. 2973, Modernizing and Ensuring PBM Accountability (MEPA) Act S. 3430, Better Mental Health Care, Lower-Cost Drugs & Extenders Act
Kidney PATIENT Act of 2023
Client: ARDELYX, INC. · Firm: ROBERTI GLOBAL (F/K/A ROBERTI WHITE, LLC)
Issues related to reimbursement under Medicare Part D H.R. 5074, the Kidney PATIENT Act
Kidney PATIENT Act of 2023
Client: ARDELYX, INC. · Firm: ROBERTI GLOBAL (F/K/A ROBERTI WHITE, LLC)
Issues related to reimbursement under Medicare Part D; H.R. 5074, Kidney PATIENT Act
Lower Costs, More Transparency Act
Client: AMERICAN PHARMACIES, INC. · Firm: ROBERTI GLOBAL (F/K/A ROBERTI WHITE, LLC)
legislative and regulatory issues related to independent pharmacy and pharmacy benefit managers (PBMs). H.R. 1613/S. 1038, Drug Price Transparency in Medicaid Act H.R. 2816, PBM Sunshine and Accountability Act H.R. 2880, Protecting Patients from PBM Abuses Act H.R. 3285, Fairness for Patient Medications Act H.R. 3561, Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act H.R. 5378, Lower Costs, More Transparency Act S. 1339, PBM Reform Act S. 1542, DRUG Act S. 2973, Modernizing and Ensuring PBM Accountability (MEPA) Act S. 3430, Better Mental Health Care, Lower-Cost Drugs & Extenders Act
WARM Act of 2023
Client: ASTELLAS PHARMA US, INC. · Firm: ROBERTI GLOBAL (F/K/A ROBERTI WHITE, LLC)
Issues related to march-in rights under the Bayh-Dole Act (Pub. L. 96-517) Women's health issues; WARM Act (H.R. 6743)
Drug Price Transparency in Medicaid Act of 2023
Client: AMERICAN PHARMACIES, INC. · Firm: ROBERTI GLOBAL (F/K/A ROBERTI WHITE, LLC)
legislative and regulatory issues related to independent pharmacy and pharmacy benefit managers (PBMs). H.R. 1613/S. 1038, Drug Price Transparency in Medicaid Act H.R. 2816, PBM Sunshine and Accountability Act H.R. 2880, Protecting Patients from PBM Abuses Act H.R. 3285, Fairness for Patient Medications Act H.R. 3561, Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act H.R. 5378, Lower Costs, More Transparency Act S. 1339, PBM Reform Act S. 1542, DRUG Act S. 2973, Modernizing and Ensuring PBM Accountability (MEPA) Act S. 3430, Better Mental Health Care, Lower-Cost Drugs & Extenders Act
Drug Price Transparency in Medicaid Act of 2023
Client: AMERICAN PHARMACIES, INC. · Firm: ROBERTI GLOBAL (F/K/A ROBERTI WHITE, LLC)
Legislative and regulatory issues related to independent pharmacies. H.R. 1613/S. 1038, Drug Price Transparency in Medicaid Act
Pharmacy Benefit Manager Reform Act
Client: AMERICAN PHARMACIES, INC. · Firm: ROBERTI GLOBAL (F/K/A ROBERTI WHITE, LLC)
legislative and regulatory issues related to independent pharmacy and pharmacy benefit managers (PBMs). H.R. 1613/S. 1038, Drug Price Transparency in Medicaid Act H.R. 2816, PBM Sunshine and Accountability Act H.R. 2880, Protecting Patients from PBM Abuses Act H.R. 3285, Fairness for Patient Medications Act H.R. 3561, Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act H.R. 5378, Lower Costs, More Transparency Act S. 1339, PBM Reform Act S. 1542, DRUG Act S. 2973, Modernizing and Ensuring PBM Accountability (MEPA) Act S. 3430, Better Mental Health Care, Lower-Cost Drugs & Extenders Act
legislative and regulatory issues related to independent pharmacy and pharmacy benefit managers (PBMs). H.R. 1613/S. 1038, Drug Price Transparency in Medicaid Act H.R. 2816, PBM Sunshine and Accountability Act H.R. 2880, Protecting Patients from PBM Abuses Act H.R. 3285, Fairness for Patient Medications Act H.R. 3561, Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act H.R. 5378, Lower Costs, More Transparency Act S. 1339, PBM Reform Act S. 1542, DRUG Act S. 2973, Modernizing and Ensuring PBM Accountability (MEPA) Act S. 3430, Better Mental Health Care, Lower-Cost Drugs & Extenders Act
Modernizing and Ensuring PBM Accountability Act
Client: AMERICAN PHARMACIES, INC. · Firm: ROBERTI GLOBAL (F/K/A ROBERTI WHITE, LLC)
legislative and regulatory issues related to independent pharmacy and pharmacy benefit managers (PBMs). H.R. 1613/S. 1038, Drug Price Transparency in Medicaid Act H.R. 2816, PBM Sunshine and Accountability Act H.R. 2880, Protecting Patients from PBM Abuses Act H.R. 3285, Fairness for Patient Medications Act H.R. 3561, Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act H.R. 5378, Lower Costs, More Transparency Act S. 1339, PBM Reform Act S. 1542, DRUG Act S. 2973, Modernizing and Ensuring PBM Accountability (MEPA) Act S. 3430, Better Mental Health Care, Lower-Cost Drugs & Extenders Act
Better Mental Health Care, Lower-Cost Drugs, and Extenders Act of 2023
Client: AMERICAN PHARMACIES, INC. · Firm: ROBERTI GLOBAL (F/K/A ROBERTI WHITE, LLC)
legislative and regulatory issues related to independent pharmacy and pharmacy benefit managers (PBMs). H.R. 1613/S. 1038, Drug Price Transparency in Medicaid Act H.R. 2816, PBM Sunshine and Accountability Act H.R. 2880, Protecting Patients from PBM Abuses Act H.R. 3285, Fairness for Patient Medications Act H.R. 3561, Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act H.R. 5378, Lower Costs, More Transparency Act S. 1339, PBM Reform Act S. 1542, DRUG Act S. 2973, Modernizing and Ensuring PBM Accountability (MEPA) Act S. 3430, Better Mental Health Care, Lower-Cost Drugs & Extenders Act
MADE in America Act
Client: UNITED SAFETY TECHNOLOGY INC. · Firm: ROBERTI GLOBAL (F/K/A ROBERTI WHITE, LLC)
Issues related to tax incentives for domestic manufacturing, H.R. 3927.S (MADE) in America Act
Permitting reform
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PNK DC LLC via ROBERTI GLOBAL (F/K/A ROBERTI WHITE, LLC)
2026 · third_quarter · Q3
Congressional outreach regarding economic development, industrial investment, community engagement, and related land use/permitting issues affecting PNK Groups industrial and data center development projects in Pennsylvania.
Congressional outreach regarding economic development, industrial investment, community engagement, and related land use/permitting issues affecting PNK Groups industrial and data center development projects in Pennsylvania.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
I AM BOUNDLESS INC via ROBERTI GLOBAL (F/K/A ROBERTI WHITE, LLC)
2026 · third_quarter · Q3
Appropriations and related federal funding support for behavioral health, intellectual and developmental disabilities programming, and capital improvements for Boundless in Ohio.
Issues related to Medicaid Home and Community-Based Services (HCBS) program integrity, including oversight, accountability, and compliance safeguards.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PALO ALTO NETWORKS, INC. via ROBERTI GLOBAL (F/K/A ROBERTI WHITE, LLC)
2026 · third_quarter · Q3
General Issues related to AI
general issues related to Cyber security
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BLUE GENES, LLC via ROBERTI GLOBAL (F/K/A ROBERTI WHITE, LLC)
2026 · third_quarter · Q3
Issues related to the America First Global Health Strategy, bilateral global health cooperation, and potential third-party clinical services support for U.S. global health assistance and partner-country health initiatives.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MOTION PICTURE ASSOCIATION OF AMERICA via ROBERTI GLOBAL (F/K/A ROBERTI WHITE, LLC)
2026 · third_quarter · Q3
General Issues Related to copyright
General Issues Related to tax
General Issues Related to communications
General Issues Related to trade
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMERICAN PHARMACIES, INC. via ROBERTI GLOBAL (F/K/A ROBERTI WHITE, LLC)
2026 · third_quarter · Q3
Issues related to independent pharmacy in Medicare, Medicaid, and other federal health programs, including Medicare Part D pharmacy access and reimbursement, Medicaid managed care pharmacy reimbursement, PBM spread pricing, direct and indirect remuneration fees, rebate and fee pass-through, pharmacy network adequacy, preferred pharmacy networks, patient steering, mail-order and specialty pharmacy practices, vertical integration, affiliated pharmacy arrangements, essential retail pharmacy access, any-willing-pharmacy protections, long-term care pharmacy access, pharmacist-provided services, Medicare drug pricing implementation, and policies affecting beneficiary access to community pharmacies.
Issues related to the TRICARE pharmacy program; NDAA reauthorization.
MARE FINANCE INVESTMENT HOLDINGS via ROBERTI GLOBAL (F/K/A ROBERTI WHITE, LLC)
2026 · third_quarter · Q3
OFAC licensing issues
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHOENIX TAILINGS via ROBERTI GLOBAL (F/K/A ROBERTI WHITE, LLC)
2026 · third_quarter · Q3
Issues related to Department of War funding programs to support onshore of rare earth metal processing.
Issues related to domestic processing of critical minerals and rare earth metals.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ARDELYX, INC. via ROBERTI GLOBAL (F/K/A ROBERTI WHITE, LLC)
2026 · third_quarter · Q3
Issues related to coverage and reimbursement under Medicare Part D.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
VALERO ENERGY CORP. via ROBERTI GLOBAL (F/K/A ROBERTI WHITE, LLC)
2026 · third_quarter · Q3
General issues related to fuel and refining
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SAMSUNG ELECTRONICS AMERICA, INC. via ROBERTI GLOBAL (F/K/A ROBERTI WHITE, LLC)
2026 · third_quarter · Q3
Outreach and monitoring related to appropriations including for energy efficiency programs, telecommunications and semiconductor incentives
Issues related to cybersecurity, supply chain, the Internet of Things and Artificial Intelligence
Outreach and monitoring related to supply chain, bilateral and multilateral trade policy and proceedings
BIOTECHNOLOGY INNOVATION ORGANIZATION (BIO) via ROBERTI GLOBAL (F/K/A ROBERTI WHITE, LLC)
2026 · third_quarter · Q3
Pharmacy Benefit Manager reform.
Issues related to drug pricing, generally; 340B Drug Pricing Program; most favored nation drug pricing; Pandemic All-Hazards Preparedness Act (PAHPA) reauthorization
Issues related to reimbursement under Medicare Part B and Part D; Most Favored Nation (MFN).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AT&T SERVICES, INC. via ROBERTI GLOBAL (F/K/A ROBERTI WHITE, LLC)
2026 · third_quarter · Q3
FCC Wireless Spectrum Rules Issues related to Handset Exclusivity Issues related to Universal Services Fund Reform Issues related to Text Messaging and Pricing Issues related to Special Access Issues related to Cyber security Issues related+A8:E8 to reimbursement under Medicare Part D// H.R. 5074, the Kidney PATIENT Act Net neutrality rule making Issues concerning broadband connectivity support
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NEW AMERICAN INDUSTRIAL ALLIANCE via ROBERTI GLOBAL (F/K/A ROBERTI WHITE, LLC)
2026 · second_quarter · Q2
Permitting reform
Permitting reform
Workforce Innovation and Opportunity Act Reauthorization
NEW AMERICAN INDUSTRIAL ALLIANCE via ROBERTI GLOBAL (F/K/A ROBERTI WHITE, LLC)
2026 · second_quarter · RR
Permitting reform, workforce innovation, and opportunity act reauthorization
Permitting reform, workforce innovation, and opportunity act reauthorization
Permitting reform, workforce innovation, and opportunity act reauthorization
PNK DC LLC via ROBERTI GLOBAL (F/K/A ROBERTI WHITE, LLC)
2026 · second_quarter · Q2
Congressional outreach regarding economic development, industrial investment, community engagement, and related land use/permitting issues affecting PNK Groups industrial and data center development projects in Pennsylvania.
Congressional outreach regarding economic development, industrial investment, community engagement, and related land use/permitting issues affecting PNK Groups industrial and data center development projects in Pennsylvania.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
I AM BOUNDLESS INC via ROBERTI GLOBAL (F/K/A ROBERTI WHITE, LLC)
2026 · second_quarter · Q2
Issues related to Medicaid Home and Community-Based Services (HCBS) program integrity, including oversight, accountability, and compliance safeguards.
FY 2027 appropriations and related federal funding support for behavioral health, intellectual and developmental disabilities programming, and capital improvements for Boundless in Ohio.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PALO ALTO NETWORKS, INC. via ROBERTI GLOBAL (F/K/A ROBERTI WHITE, LLC)
2026 · second_quarter · Q2
General Issues related to AI
general issues related to Cyber security
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BLUE GENES, LLC via ROBERTI GLOBAL (F/K/A ROBERTI WHITE, LLC)
2026 · second_quarter · Q2
Issues related to coverage of pharmacogenomics under TRICARE, Medicare and Veterans Health Administration
Issues related to the America First Global Health Strategy, bilateral global health cooperation, and potential third-party clinical services support for U.S. global health assistance and partner-country health initiatives.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MOTION PICTURE ASSOCIATION OF AMERICA via ROBERTI GLOBAL (F/K/A ROBERTI WHITE, LLC)
2026 · second_quarter · Q2
General Issues Related to communications
General Issues Related to copyright
General Issues Related to trade
AMERICAN PHARMACIES, INC. via ROBERTI GLOBAL (F/K/A ROBERTI WHITE, LLC)
2026 · second_quarter · Q2
Issues related to independent pharmacy, pharmacy benefit manager practices, prescription drug access and affordability, pharmacy networks, reimbursement, contract terms, patient steering, spread pricing, direct and indirect remuneration fees, rebate and fee transparency, audit rights, claims data transparency, vertical integration, affiliated pharmacy arrangements, mail-order and specialty pharmacy practices, any-willing-pharmacy protections, network adequacy, pharmacy access standards, and policies affecting family-owned and community pharmacies in the commercial market.
Issues related to independent pharmacy in Medicare, Medicaid, and other federal health programs, including Medicare Part D pharmacy access and reimbursement, Medicaid managed care pharmacy reimbursement, PBM spread pricing, direct and indirect remuneration fees, rebate and fee pass-through, pharmacy network adequacy, preferred pharmacy networks, patient steering, mail-order and specialty pharmacy practices, vertical integration, affiliated pharmacy arrangements, essential retail pharmacy access, any-willing-pharmacy protections, long-term care pharmacy access, pharmacist-provided services, Medicare drug pricing implementation, and policies affecting beneficiary access to community pharmacies.
MARE FINANCE INVESTMENT HOLDINGS via ROBERTI GLOBAL (F/K/A ROBERTI WHITE, LLC)
2026 · second_quarter · Q2
OFAC licensing issues
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHOENIX TAILINGS via ROBERTI GLOBAL (F/K/A ROBERTI WHITE, LLC)
2026 · second_quarter · Q2
Issues related to domestic processing of critical minerals and rare earth metals.
Issues related to Department of War funding programs to support onshore of rare earth metal processing.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ARDELYX, INC. via ROBERTI GLOBAL (F/K/A ROBERTI WHITE, LLC)
2026 · second_quarter · Q2
Issues related to coverage and reimbursement under Medicare Part D.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
VALERO ENERGY CORP. via ROBERTI GLOBAL (F/K/A ROBERTI WHITE, LLC)
2026 · second_quarter · Q2
General issues related to fuel and refining
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SAMSUNG ELECTRONICS AMERICA, INC. via ROBERTI GLOBAL (F/K/A ROBERTI WHITE, LLC)
2026 · second_quarter · Q2
Outreach and monitoring relating to technology issues, including 5G, spectrum and wireless broadband, affecting the telecommunications industry.
Implementation of CHIPS and Science Act, PL 117-167; issues related to supply chain
Outreach and monitoring related to appropriations including for energy efficiency programs, telecommunications and semiconductor incentives
BIOTECHNOLOGY INNOVATION ORGANIZATION (BIO) via ROBERTI GLOBAL (F/K/A ROBERTI WHITE, LLC)
2026 · second_quarter · Q2
BIOSECURE Act/S. Amdt. 3236 to S. 2296, the National Defense Authorization Act for FY2026.
Issues related to reimbursement under Medicare Part B and Part D; Most Favored Nation (MFN).
Issues related to drug pricing, generally; 340B Drug Pricing Program; pharmacy benefit managers; drug patents and patent reporting requirements; H.R. 1262/S. 932, Give Kids a Chance Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AT&T SERVICES, INC. via ROBERTI GLOBAL (F/K/A ROBERTI WHITE, LLC)
2026 · second_quarter · Q2
FCC Wireless Spectrum Rules Issues related to Handset Exclusivity Issues related to Universal Services Fund Reform Issues related to Text Messaging and Pricing Issues related to Special Access Issues related to Cyber security Issues related+A8:E8 to reimbursement under Medicare Part D// H.R. 5074, the Kidney PATIENT Act Net neutrality rule making Issues concerning broadband connectivity support
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PNK DC LLC via ROBERTI GLOBAL (F/K/A ROBERTI WHITE, LLC)
2026 · first_quarter · Q1
Congressional outreach regarding economic development, industrial investment, community engagement, and related land use/permitting issues affecting PNK Groups industrial and data center development projects in Pennsylvania.
Congressional outreach regarding economic development, industrial investment, community engagement, and related land use/permitting issues affecting PNK Groups industrial and data center development projects in Pennsylvania.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
I AM BOUNDLESS INC via ROBERTI GLOBAL (F/K/A ROBERTI WHITE, LLC)
2026 · first_quarter · Q1
FY 2027 appropriations and related federal funding support for behavioral health, intellectual and developmental disabilities programming, and capital improvements for Boundless in Ohio.
Issues related to Medicaid Home and Community-Based Services (HCBS) program integrity, including oversight, accountability, and compliance safeguards.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PNK DC LLC via ROBERTI GLOBAL (F/K/A ROBERTI WHITE, LLC)
2026 · first_quarter · RR
Congressional outreach regarding economic development, industrial investment, community engagement, and related land use/permitting issues affecting PNK Groups industrial and data center development projects in Pennsylvania.
Congressional outreach regarding economic development, industrial investment, community engagement, and related land use/permitting issues affecting PNK Groups industrial and data center development projects in Pennsylvania.
PALO ALTO NETWORKS, INC. via ROBERTI GLOBAL (F/K/A ROBERTI WHITE, LLC)
2026 · first_quarter · Q1
General Issues related to AI
general issues related to Cyber security
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BLUE GENES, LLC via ROBERTI GLOBAL (F/K/A ROBERTI WHITE, LLC)
2026 · first_quarter · Q1
Issues related to coverage of pharmacogenomics under TRICARE, Medicare and Veterans Health Administration
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MOTION PICTURE ASSOCIATION OF AMERICA via ROBERTI GLOBAL (F/K/A ROBERTI WHITE, LLC)
2026 · first_quarter · Q1
General Issues Related to trade
General Issues Related to tax
General Issues Related to copyright
AMERICAN PHARMACIES, INC. via ROBERTI GLOBAL (F/K/A ROBERTI WHITE, LLC)
2026 · first_quarter · Q1
Issues related to independent pharmacy, including Medicare and Medicaid reimbursement; H.R. 1, One Big Beautiful Bill Act; H.R. 4317, Pharmacy Benefit Manager (PBM) Reform Act; S. 882, Patients Before Middlemen (PBM) Act; H.R. 5031, Preserving Patient Access to Long-Term Care Pharmacies Act; H.R. 3164/S. 2426, Equitable Community Access to Pharmacist Services (ECAPS) Act; H.R. 2484, Seniors Access to Critical Medications Act; IRA Medicare Drug Price Negotiation program implementation.
Issues related to independent pharmacy, including insurance coverage, network, and reimbursement; S. 526, Pharmacy Benefit Transparency Act; H.R. 2214, Delinking Revenue from Unfair Gouging (DRUG) Act.
MARE FINANCE INVESTMENT HOLDINGS via ROBERTI GLOBAL (F/K/A ROBERTI WHITE, LLC)
2026 · first_quarter · Q1
OFAC licensing issues
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHOENIX TAILINGS via ROBERTI GLOBAL (F/K/A ROBERTI WHITE, LLC)
2026 · first_quarter · Q1
Issues related to Department of War funding programs to support onshore of rare earth metal processing.
Issues related to domestic processing of critical minerals and rare earth metals.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ARDELYX, INC. via ROBERTI GLOBAL (F/K/A ROBERTI WHITE, LLC)
2026 · first_quarter · Q1
Issues related to coverage and reimbursement under Medicare Part D.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
VALERO ENERGY CORP. via ROBERTI GLOBAL (F/K/A ROBERTI WHITE, LLC)
2026 · first_quarter · Q1
General issues related to fuel and refining
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SAMSUNG ELECTRONICS AMERICA, INC. via ROBERTI GLOBAL (F/K/A ROBERTI WHITE, LLC)
2026 · first_quarter · Q1
Outreach and monitoring relating to technology issues, including 5G, spectrum and wireless broadband, affecting the telecommunications industry.
Outreach and monitoring related to supply chain, bilateral and multilateral trade policy and proceedings
Outreach and monitoring related to appropriations including for energy efficiency programs, telecommunications and semiconductor incentives
BIOTECHNOLOGY INNOVATION ORGANIZATION (BIO) via ROBERTI GLOBAL (F/K/A ROBERTI WHITE, LLC)
2026 · first_quarter · Q1
BIOSECURE Act/S. Amdt. 3236 to S. 2296, the National Defense Authorization Act for FY2026.
Issues related to reimbursement under Medicare Part B and Part D; Most Favored Nation (MFN).
Issues related to drug pricing, generally; 340B Drug Pricing Program; pharmacy benefit managers; drug patents and patent reporting requirements; H.R. 1262/S. 932, Give Kids a Chance Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AT&T SERVICES, INC. via ROBERTI GLOBAL (F/K/A ROBERTI WHITE, LLC)
2026 · first_quarter · Q1
FCC Wireless Spectrum Rules Issues related to Handset Exclusivity Issues related to Universal Services Fund Reform Issues related to Text Messaging and Pricing Issues related to Special Access Issues related to Cyber security Issues related+A8:E8 to reimbursement under Medicare Part D// H.R. 5074, the Kidney PATIENT Act Net neutrality rule making Issues concerning broadband connectivity support
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
I AM BOUNDLESS INC via ROBERTI GLOBAL (F/K/A ROBERTI WHITE, LLC)
2026 · first_quarter · RR
Issues related to Medicaid Home and Community-Based Services (HCBS) and Congressionally Directed Spending
Issues related to Medicaid Home and Community-Based Services (HCBS) and Congressionally Directed Spending
PALO ALTO NETWORKS, INC. via ROBERTI GLOBAL (FKA ROBERTI WHITE, LLC)
2025 · fourth_quarter · Q4
general issues related to Cyber security
General Issues related to AI
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MOTION PICTURE ASSOCIATION OF AMERICA via ROBERTI GLOBAL (FKA ROBERTI WHITE, LLC)
2025 · fourth_quarter · Q4
General Issues Related to communications
General Issues Related to copywrite
General Issues Related to trade
VALERO ENERGY CORP. via ROBERTI GLOBAL (FKA ROBERTI WHITE, LLC)
2025 · fourth_quarter · Q4
General issues related to fuel and refining
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHOENIX TAILINGS via ROBERTI GLOBAL (FKA ROBERTI WHITE, LLC)
2025 · fourth_quarter · Q4
Issues related to domestic processing of critical minerals and rare earth metals.
Issues related to Department of War funding programs to support onshore of rare earth metal processing.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MARE FINANCE INVESTMENT HOLDINGS via ROBERTI GLOBAL (FKA ROBERTI WHITE, LLC)
2025 · fourth_quarter · Q4
OFAC licensing issues
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BLUE GENES, LLC via ROBERTI GLOBAL (FKA ROBERTI WHITE, LLC)
2025 · fourth_quarter · Q4
Issues related to coverage of pharmacogenomics under TRICARE, Medicare and Veterans Health Administration
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BIOTECHNOLOGY INNOVATION ORGANIZATION (BIO) via ROBERTI GLOBAL (FKA ROBERTI WHITE, LLC)
2025 · fourth_quarter · Q4
Issues related to reimbursement under Medicare Part B and Part D; Most Favored Nation (MFN).
Issues related to drug pricing, generally; 340B Drug Pricing Program; pharmacy benefit managers; drug patents and patent reporting requirements; H.R. 1262/S. 932, Give Kids a Chance Act.
BIOSECURE Act/S. Amdt. 3236 to S. 2296, the National Defense Authorization Act for FY2026.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AT&T SERVICES, INC. via ROBERTI GLOBAL (FKA ROBERTI WHITE, LLC)
2025 · fourth_quarter · Q4
FCC Wireless Spectrum Rules Issues related to Handset Exclusivity Issues related to Universal Services Fund Reform Issues related to Text Messaging and Pricing Issues related to Special Access Issues related to Cyber security Issues related+A8:E8 to reimbursement under Medicare Part D// H.R. 5074, the Kidney PATIENT Act Net neutrality rule making Issues concerning broadband connectivity support
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ARDELYX, INC. via ROBERTI GLOBAL (FKA ROBERTI WHITE, LLC)
2025 · fourth_quarter · Q4
Issues related to coverage and reimbursement under Medicare Part D.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMERICAN PHARMACIES, INC. via ROBERTI GLOBAL (FKA ROBERTI WHITE, LLC)
2025 · fourth_quarter · Q4
Issues related to independent pharmacy, including insurance coverage, network, and reimbursement; S. 526, Pharmacy Benefit Transparency Act; H.R. 2214, Delinking Revenue from Unfair Gouging (DRUG) Act.
Issues related to independent pharmacy, including Medicare and Medicaid reimbursement; H.R. 1, One Big Beautiful Bill Act; H.R. 4317, Pharmacy Benefit Manager (PBM) Reform Act; S. 882, Patients Before Middlemen (PBM) Act; H.R. 5031, Preserving Patient Access to Long-Term Care Pharmacies Act; H.R. 3164/S. 2426, Equitable Community Access to Pharmacist Services (ECAPS) Act; H.R. 2484, Seniors Access to Critical Medications Act; IRA Medicare Drug Price Negotiation program implementation.
AIRLINES FOR AMERICA (FORMERLY AIR TRANSPORT ASSOCIATION OF AMERICA INC.) via ROBERTI GLOBAL (FKA ROBERTI WHITE, LLC)
2025 · fourth_quarter · Q4
Aviation, aircraft, and airline issues FAA Reauthorization regarding ATC reform
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SAMSUNG ELECTRONICS AMERICA, INC. via ROBERTI GLOBAL (FKA ROBERTI WHITE, LLC)
2025 · fourth_quarter · Q4
Outreach and monitoring relating to technology issues, including 5G, spectrum and wireless broadband, affecting the telecommunications industry.
Outreach and monitoring related to appropriations including for energy efficiency programs, telecommunications and semiconductor incentives
Outreach and monitoring related to supply chain, bilateral and multilateral trade policy and proceedings
SAMSUNG ELECTRONICS AMERICA, INC. via ROBERTI GLOBAL (FKA ROBERTI WHITE, LLC)
2025 · third_quarter · Q3
Outreach and monitoring relating to technology issues, including 5G, spectrum and wireless broadband, affecting the telecommunications industry.
Outreach and monitoring related to appropriations including for energy efficiency programs, telecommunications and semiconductor incentives
Outreach and monitoring related to supply chain, bilateral and multilateral trade policy and proceedings
PALO ALTO NETWORKS, INC. via ROBERTI GLOBAL (FKA ROBERTI WHITE, LLC)
2025 · third_quarter · Q3
general issues related to Cyber security
General Issues related to AI
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MOTION PICTURE ASSOCIATION OF AMERICA via ROBERTI GLOBAL (FKA ROBERTI WHITE, LLC)
2025 · third_quarter · Q3
General Issues Related to communications
General Issues Related to copywrite
General Issues Related to trade
VALERO ENERGY CORP. via ROBERTI GLOBAL (FKA ROBERTI WHITE, LLC)
2025 · third_quarter · Q3
General issues related to fuel and refining
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHOENIX TAILINGS via ROBERTI GLOBAL (FKA ROBERTI WHITE, LLC)
2025 · third_quarter · Q3
Issues related to domestic processing of critical minerals and rare earth metals.
Issues related to Department of War funding programs to support onshore of rare earth metal processing.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MARE FINANCE INVESTMENT HOLDINGS via ROBERTI GLOBAL (FKA ROBERTI WHITE, LLC)
2025 · third_quarter · Q3
OFAC licensing issues
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BLUE GENES, LLC via ROBERTI GLOBAL (FKA ROBERTI WHITE, LLC)
2025 · third_quarter · Q3
Issues related to coverage of pharmacogenomics under TRICARE, Medicare and Veterans Health Administration
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BIOTECHNOLOGY INNOVATION ORGANIZATION (BIO) via ROBERTI GLOBAL (FKA ROBERTI WHITE, LLC)
2025 · third_quarter · Q3
Issues related to reimbursement under Medicare Part B and Part D; Most Favored Nation (MFN).
Issues related to drug pricing, generally; 340B Drug Pricing Program; pharmacy benefit managers; drug patents and patent reporting requirements; H.R. 1262/S. 932, Give Kids a Chance Act.
BIOSECURE Act/S. Amdt. 3236 to S. 2296, the National Defense Authorization Act for FY2026.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AT&T SERVICES, INC. via ROBERTI GLOBAL (FKA ROBERTI WHITE, LLC)
2025 · third_quarter · Q3
FCC Wireless Spectrum Rules Issues related to Handset Exclusivity Issues related to Universal Services Fund Reform Issues related to Text Messaging and Pricing Issues related to Special Access Issues related to Cyber security Issues related+A8:E8 to reimbursement under Medicare Part D// H.R. 5074, the Kidney PATIENT Act Net neutrality rule making Issues concerning broadband connectivity support
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ARDELYX, INC. via ROBERTI GLOBAL (FKA ROBERTI WHITE, LLC)
2025 · third_quarter · Q3
Issues related to coverage and reimbursement under Medicare Part D.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMERICAN PHARMACIES, INC. via ROBERTI GLOBAL (FKA ROBERTI WHITE, LLC)
2025 · third_quarter · Q3
Issues related to independent pharmacy, including insurance coverage, network, and reimbursement; S. 526, Pharmacy Benefit Transparency Act; H.R. 2214, Delinking Revenue from Unfair Gouging (DRUG) Act.
Issues related to independent pharmacy, including Medicare and Medicaid reimbursement; H.R. 1, One Big Beautiful Bill Act; H.R. 4317, Pharmacy Benefit Manager (PBM) Reform Act; S. 882, Patients Before Middlemen (PBM) Act; H.R. 5031, Preserving Patient Access to Long-Term Care Pharmacies Act; H.R. 3164/S. 2426, Equitable Community Access to Pharmacist Services (ECAPS) Act; H.R. 2484, Seniors Access to Critical Medications Act; IRA Medicare Drug Price Negotiation program implementation.
AIRLINES FOR AMERICA (FORMERLY AIR TRANSPORT ASSOCIATION OF AMERICA INC.) via ROBERTI GLOBAL (FKA ROBERTI WHITE, LLC)
2025 · third_quarter · Q3
Aviation, aircraft, and airline issues FAA Reauthorization regarding ATC reform
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PALO ALTO NETWORKS, INC. via ROBERTI GLOBAL (FKA ROBERTI WHITE, LLC)
2025 · second_quarter · Q2
general issues related to Cyber security
General Issues related to AI
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BLUE GENES, LLC via ROBERTI GLOBAL (FKA ROBERTI WHITE, LLC)
2025 · second_quarter · Q2
Issues related to coverage of pharmacogenomics under TRICARE, Medicare and Veterans Health Administration
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MOTION PICTURE ASSOCIATION OF AMERICA via ROBERTI GLOBAL (FKA ROBERTI WHITE, LLC)
2025 · second_quarter · Q2
General Issues Related to communications
General Issues Related to copywrite
General Issues Related to trade
AMERICAN PHARMACIES, INC. via ROBERTI GLOBAL (FKA ROBERTI WHITE, LLC)
2025 · second_quarter · Q2
Issues related to independent pharmacy, including Medicare and Medicaid reimbursement; H.R. 1, One Big Beautiful Bill Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MARE FINANCE INVESTMENT HOLDINGS via ROBERTI GLOBAL (FKA ROBERTI WHITE, LLC)
2025 · second_quarter · Q2
OFAC licensing issues
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHOENIX TAILINGS via ROBERTI GLOBAL (FKA ROBERTI WHITE, LLC)
2025 · second_quarter · Q2
Appropriations - Department of Energy; Department of Interior
Issues related to the processing of critical minerals and rare earth metals used in magnets for electrification
Filing targets: Energy, Dept of, HOUSE OF REPRESENTATIVES, Interior, Dept of (DOI), SENATE
ARDELYX, INC. via ROBERTI GLOBAL (FKA ROBERTI WHITE, LLC)
2025 · second_quarter · Q2
Issues related to reimbursement under Medicare Part D; H.R. 5074/S.4510, the Kidney PATIENT Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
VALERO ENERGY CORP. via ROBERTI GLOBAL (FKA ROBERTI WHITE, LLC)
2025 · second_quarter · Q2
General issues related to fuel and refining
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SAMSUNG ELECTRONICS AMERICA, INC. via ROBERTI GLOBAL (FKA ROBERTI WHITE, LLC)
2025 · second_quarter · Q2
Outreach and monitoring relating to technology issues, including 5G, spectrum and wireless broadband, affecting the telecommunications industry.
Outreach and monitoring related to appropriations including for energy efficiency programs, telecommunications and semiconductor incentives
Outreach and monitoring related to supply chain, bilateral and multilateral trade policy and proceedings
BIOTECHNOLOGY INNOVATION ORGANIZATION (BIO) via ROBERTI GLOBAL (FKA ROBERTI WHITE, LLC)
2025 · second_quarter · Q2
Issues related to reimbursement under Medicare Part B Issues related to Medicare Part D, generally Issues related to the 340B Drug Pricing Program
Issues related to drug pricing and value, generally Issues related to pharmacy benefit managers and drug rebate reform Issues related to drug patents and patent reporting requirements H.R. 946, the ORPHAN Cures Act H.R. 1262/S. 932, the Give Kids a Chance Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AT&T SERVICES, INC. via ROBERTI GLOBAL (FKA ROBERTI WHITE, LLC)
2025 · second_quarter · Q2
FCC Wireless Spectrum Rules Issues related to Handset Exclusivity Issues related to Universal Services Fund Reform Issues related to Text Messaging and Pricing Issues related to Special Access Issues related to Cyber security Issues related+A8:E8 to reimbursement under Medicare Part D// H.R. 5074, the Kidney PATIENT Act Net neutrality rule making Issues concerning broadband connectivity support
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AIRLINES FOR AMERICA (FORMERLY AIR TRANSPORT ASSOCIATION OF AMERICA INC.) via ROBERTI GLOBAL (FKA ROBERTI WHITE, LLC)
2025 · second_quarter · Q2
Aviation, aircraft, and airline issues FAA Reauthorization regarding ATC reform
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AT&T SERVICES, INC. via ROBERTI GLOBAL (FKA ROBERTI WHITE, LLC)
2025 · first_quarter · Q1
FCC Wireless Spectrum Rules Issues related to Handset Exclusivity Issues related to Universal Services Fund Reform Issues related to Text Messaging and Pricing Issues related to Special Access Issues related to Cyber security Issues related+A8:E8 to reimbursement under Medicare Part D// H.R. 5074, the Kidney PATIENT Act Net neutrality rule making Issues concerning broadband connectivity support
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PALO ALTO NETWORKS, INC. via ROBERTI GLOBAL (FKA ROBERTI WHITE, LLC)
2025 · first_quarter · Q1
general issues related to Cyber security
General Issues related to AI
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BLUE GENES, LLC via ROBERTI GLOBAL (FKA ROBERTI WHITE, LLC)
2025 · first_quarter · Q1
Issues related to coverage of pharmacogenomics under TRICARE, Medicare and Veterans Health Administration
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MOTION PICTURE ASSOCIATION OF AMERICA via ROBERTI GLOBAL (FKA ROBERTI WHITE, LLC)
2025 · first_quarter · Q1
General Issues Related to communications
General Issues Related to copywrite
General Issues Related to trade
AMERICAN PHARMACIES, INC. via ROBERTI GLOBAL (FKA ROBERTI WHITE, LLC)
2025 · first_quarter · Q1
Issues related to the support and preservation of independent pharmacy, including Medicare and Medicaid reimbursement, and Pharmacy Benefit Management (PBM reform).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MARE FINANCE INVESTMENT HOLDINGS via ROBERTI GLOBAL (FKA ROBERTI WHITE, LLC)
2025 · first_quarter · Q1
OFAC licensing issues
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHOENIX TAILINGS via ROBERTI GLOBAL (FKA ROBERTI WHITE, LLC)
2025 · first_quarter · Q1
Appropriations - Department of Energy; Department of Interior
Issues related to the processing of critical minerals and rare earth metals used in magnets for both civilian and military applications
Filing targets: Energy, Dept of, HOUSE OF REPRESENTATIVES, Interior, Dept of (DOI), SENATE
ARDELYX, INC. via ROBERTI GLOBAL (FKA ROBERTI WHITE, LLC)
2025 · first_quarter · Q1
Issues related to the incorporation of oral drugs indicated for the reduction, management, or control of the serum phosphate of an individual into the End-Stage Renal Disease (ESRD) Prospective Payment System.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
VALERO ENERGY CORP. via ROBERTI GLOBAL (FKA ROBERTI WHITE, LLC)
2025 · first_quarter · Q1
General issues related to fuel and refining
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SAMSUNG ELECTRONICS AMERICA, INC. via ROBERTI GLOBAL (FKA ROBERTI WHITE, LLC)
2025 · first_quarter · Q1
Outreach and monitoring relating to technology issues, including 5G, spectrum and wireless broadband, affecting the telecommunications industry.
Outreach and monitoring related to appropriations including for energy efficiency programs, telecommunications and semiconductor incentives
Outreach and monitoring related to supply chain, bilateral and multilateral trade policy and proceedings
BIOTECHNOLOGY INNOVATION ORGANIZATION (BIO) via ROBERTI GLOBAL (FKA ROBERTI WHITE, LLC)
2025 · first_quarter · Q1
Issues related to reimbursement under Medicare Part B Issues related to Medicare Part D, generally Issues related to the 340B Drug Pricing Program
Issues related to drug pricing and value, generally Issues related to pharmacy benefit managers and drug rebate reform Issues related to drug patents and patent reporting requirements H.R. 946, the ORPHAN Cures Act H.R. 1262/S. 932, the Give Kids a Chance Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AIRLINES FOR AMERICA (FORMERLY AIR TRANSPORT ASSOCIATION OF AMERICA INC.) via ROBERTI GLOBAL (FKA ROBERTI WHITE, LLC)
2025 · first_quarter · Q1
Aviation, aircraft, and airline issues FAA Reauthorization regarding ATC reform
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PALO ALTO NETWORKS, INC. via ROBERTI GLOBAL (F/K/A ROBERTI WHITE, LLC)
2024 · fourth_quarter · Q4
general issues related to cyber security issues
general issuesrelated to AI
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BLUE GENES, LLC via ROBERTI GLOBAL (F/K/A ROBERTI WHITE, LLC)
2024 · fourth_quarter · Q4
Issues related to coverage of pharmacogenomics under TRICARE, Medicare and Veterans Health Administration
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MOTION PICTURE ASSOCIATION OF AMERICA via ROBERTI GLOBAL (F/K/A ROBERTI WHITE, LLC)
2024 · fourth_quarter · Q4
General Issues Related to communications
General Issues Related to trade
General Issues Related to tax
AMERICAN PHARMACIES, INC. via ROBERTI GLOBAL (F/K/A ROBERTI WHITE, LLC)
2024 · fourth_quarter · Q4
Issues related to independent pharmacy, including Medicare and Medicaid reimbursement; H.R. 5378, the Lower Costs, More Transparency Act; S. 1339, the PBM Reform Act; S. 3430, the Better Mental Health Care, Lower-Cost Drugs & Extenders Act; S. 2973, the Modernizing & Ensuring PBM Accountability Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MARE FINANCE INVESTMENT HOLDINGS via ROBERTI GLOBAL (F/K/A ROBERTI WHITE, LLC)
2024 · fourth_quarter · Q4
OFAC licensing issues
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHOENIX TAILINGS via ROBERTI GLOBAL (F/K/A ROBERTI WHITE, LLC)
2024 · fourth_quarter · Q4
Issues related to the processing of critical minerals and rare earth metals used in magnets for electrification.
Appropriations - Department of Energy; Department of Interior National Defense Authorization Act
Filing targets: Energy, Dept of, HOUSE OF REPRESENTATIVES, Interior, Dept of (DOI), SENATE
ARDELYX, INC. via ROBERTI GLOBAL (F/K/A ROBERTI WHITE, LLC)
2024 · fourth_quarter · Q4
Issues related to reimbursement under Medicare Part D; H.R. 5074/S.4510, the Kidney PATIENT Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
VALERO ENERGY CORP. via ROBERTI GLOBAL (F/K/A ROBERTI WHITE, LLC)
2024 · fourth_quarter · Q4
General issues related to fuel and refining
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to independent pharmacy, pharmacy benefit manager practices, prescription drug access and affordability, pharmacy networks, reimbursement, contract terms, patient steering, spread pricing, direct and indirect remuneration fees, rebate and fee transparency, audit rights, claims data transparency, vertical integration, affiliated pharmacy arrangements, mail-order and specialty pharmacy practices, any-willing-pharmacy protections, network adequacy, pharmacy access standards, and policies affecting family-owned and community pharmacies in the commercial market.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Outreach and monitoring relating to technology issues, including 5G, spectrum and wireless broadband, affecting the telecommunications industry.
Implementation of CHIPS and Science Act, PL 117-167; issues related to supply chain
Issues related to the CHIPS and Science Act (P.L. 117-167) Section 48D Advanced Manufacturing Investment Credit, and other corporate and international tax policies.
Issues related to digital divide, STEM education, and issues related to workforce development.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Workforce Innovation and Opportunity Act Reauthorization
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Permitting reform, workforce innovation, and opportunity act reauthorization
General Issues Related to tax
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to the TRICARE pharmacy program; NDAA reauthorization.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to digital divide, STEM education, and issues related to workforce development.
Outreach and monitoring related to supply chain, bilateral and multilateral trade policy and proceedings
Issues related to cybersecurity, supply chain, the Internet of Things and Artificial Intelligence
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
General Issues Related to communications
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
TRICARE pharmacy program.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to digital divide, STEM education, and issues related to workforce development.
Implementation of CHIPS and Science Act, PL 117-167
Issues related to cybersecurity, the Internet of Things and Artificial Intelligence
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
General Issues Related to tax
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
TRICARE pharmacy program.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to cybersecurity, the Internet of Things and Artificial Intelligence
Implementation of CHIPS and Science Act, PL 117-167
Issues related to digital divide, STEM education, and issues related to workforce development.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to cybersecurity, the Internet of Things and Artificial Intelligence
Implementation of CHIPS and Science Act, PL 117-167
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
General Issues Related to tax
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
TRICARE pharmacy program.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
General Issues Related to tax
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to cybersecurity, the Internet of Things and Artificial Intelligence
Implementation of CHIPS and Science Act, PL 117-167
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
General Issues Related to tax
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to cybersecurity, the Internet of Things and Artificial Intelligence
Implementation of CHIPS and Science Act, PL 117-167
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
General Issues Related to copywrite
Filing targets: HOUSE OF REPRESENTATIVES, SENATE